ENDPOINTS NEWS3h
Ex­clu­sive: Buck­ing gene edit­ing down­turn, Tune rais­es $175M to bring epi­ge­net­ic edit­ing to clin­ic
Tune Therapeutics raises $175M Series B for epigenetic editing, with hepatitis B drug Tune-401 in the clinic. NEA, Yosemite, ...
ENDPOINTS NEWS4h
Break­ing: J&J looks at po­ten­tial bid for In­tra-Cel­lu­lar — re­port
Johnson & Johnson is considering an acquisition of CNS drugmaker Intra-Cellular Therapies, according to anonymous sources ...
ENDPOINTS NEWS9h
Post-Hoc: The em­bryo edit­ing de­bate is back
Nature journal publishes article suggesting embryo gene editing could prevent major diseases, sparking debate. Study by Peter ...